Formulation and method for treating skeletal muscle degeneration caused by malnutrition and disease
OwnerEnitan A. Bababunmiinventor
Life of this patent
Estimating the term…
Abstract
A formulation is provided for the treatment of the adverse affects of skeletal muscle degenerative diseases prevalent in humans in developing countries. The formulation typically includes a first component including at least one of jasmone, a jasmonate, jasmonic acid, oxo-phytodienoic acid, and a second component including at least one of an antioxidant and carnitine. Additionally, soy milk may be utilized as a delivery vehicle for the formulation for oral ingestion by a subject. The formulation is designed to replenish energy levels in disease infected muscle cells, reinstate calcium homeostasis within the muscle cells, and reduce the activity of oxidizing free radical reactions typically caused by muscle degenerative diseases.
Claims22
A formulation comprising jasmone and carnitine.
A formulation comprising a first component selected from the group consisting of a jasmonate, jasmonic acid, oxo-phytodienoic acid and combinations thereof, and a second component comprising carnitine.
A formulation comprising carnitine, an isoflavone selected from the group consisting of genistein, daidzein and combinations thereof, and a jasmonate family component selected from the group consisting of a jasmonate, jasmonic acid, oxo-phytodienoic acid and combinations thereof.
A method of manufacturing a formulation comprising:
- (a) combining a selected amount of a first component with a selected amount of a second component, wherein the first component is selected from the group consisting of jasmone, a jasmonate, jasmonic acid, oxo-phytodienoic acid and combinations thereof, and the second component comprises carnitine.
A formulation comprising soy milk and at least one of a jasmonate, jasmonic acid and oxo-phytodienoic acid.
Dependencies are inferred from the claim text.